Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

Waldencast (NASDAQ: WALD) announced that Obagi Medical has launched the ALOHA Real-World Program with Platinum Dermatology Partners as the initial launch partner to generate real-world evidence for Obagi saypha MagIQ.

Rhea-AI Summary

Waldencast (NASDAQ: WALD) announced that Obagi Medical has launched the ALOHA Real-World Program with Platinum Dermatology Partners as the initial launch partner to generate real-world evidence for Obagi saypha MagIQ. The program will provide Platinum providers hands-on use of the injectable, standardized data capture across multiple practices, and a structured evaluation of complete Obagi protocols. Initial findings are slated for presentation at Platinum’s annual Summit in Dallas in September 2026 and at key industry conferences to demonstrate real-world outcomes and support the product’s differentiated launch strategy.

Positive

• Platinum named as launch partner to generate real-world evidence for Obagi saypha MagIQ
• Program includes standardized data capture across Platinum’s ~120 locations and ~400 providers

Negative

• None.

Argus Jan 26 session

+0.57% close to close Open Argus

Details

News Market Reaction – WALD

On Jan 26, the day this news came out, WALD closed 0.57% above the previous close.

Data tracked by StockTitan Argus for the Jan 26 session.

Key Figures

ALOHA presentation timing: September MACRO Core reference: 2025; 11(7):487 Brand legacy: 35+ years +5 more

ALOHA presentation timing

September

Initial ALOHA findings to be presented at Platinum Summit in Dallas

MACRO Core reference

2025; 11(7):487

Journal citation for framework comparing HA filler crosslinking technologies

Brand legacy

35+ years

Obagi Medical experience in research-based skincare

Platinum locations

over 120 locations

Platinum Dermatology Partners footprint across five U.S. states

Platinum providers

nearly 400 providers

Size of Platinum Dermatology Partners clinical provider network

Top 10 ranking

Top 10

Obagi among Top 10 U.S. professional skin care brands in 2024

Share price

$1.74

Pre-news price level on day of ALOHA collaboration announcement

52-week range

$1.45–$4.10

Pre-news 52-week low and high for WALD shares

Historical Context

5 past events · Latest: Jan 21

5 events

1. Jan 21

   Program launch news

   24h Move

   +6.9%

   Launch of ALOHA program to support Obagi saypha MagIQ real-world rollout.

2. Nov 24

   Earnings and update

   24h Move

   -6.5%

   Q2 and H1 2025 results with large goodwill impairments and mixed brand trends.

3. Nov 16

   Clinical data update

   24h Move

   +4.2%

   New clinical data on hyaluronic acid injectables and Nu-Cil Scalp Serum.

4. Nov 14

   Balance sheet actions

   24h Move

   +0.0%

   Sale of Obagi Japan trademark and entry into new term loan facility.

5. Nov 12

   Earnings timing update

   24h Move

   +0.0%

   Announcement of upcoming Q2 and Q3 2025 earnings release dates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

real-world data, pivotal trials, injectable, hyaluronic acid, +2 more

6 terms

real-world data medical

"Platinum will help generate real-world data to translate the clinical safety"

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

pivotal trials medical

"efficacy demonstrated in FDA pivotal trials into everyday practice"

Pivotal trials are the large, definitive clinical studies designed to show whether a drug or medical device works and is safe enough for regulatory approval. Investors watch them like a final exam for a product: passing typically clears the way to sell the therapy and generate revenue, while failing can delay or block approval and sharply reduce a company's value.

injectable medical

"introducing this innovative injectable across Platinum’s practices."

A product described as an "injectable" is a medicine or vaccine formulated to be given by needle, syringe, or infusion rather than taken by mouth. For investors it matters because injectables often require specialized manufacturing, cold storage and trained staff to administer, which can raise costs, create supply-chain risks and form higher barriers to competitors—factors that influence a product’s price, market reach and long-term revenue potential.

hyaluronic acid medical

"Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program."

A naturally occurring molecule that acts like a tiny sponge, holding water in skin, joints and eyes to keep tissues plump and lubricated. Investors track products containing hyaluronic acid because they power large markets—such as skincare, injectable fillers, eye drops and wound treatments—so demand, regulatory approvals, manufacturing capacity and raw-material costs can meaningfully affect a company’s sales and profit outlook.

proprietary technical

"utilizes proprietary MACRO Core Technology to create a stable"

Proprietary describes something a company owns or controls exclusively—such as a formula, method, software, dataset, or business process—often protected by secrecy, patents, or contracts. For investors it signals potential competitive advantage or unique value, like a baker’s secret recipe that attracts customers and can produce higher profits, but it also brings risks if the company fails to defend or monetize that exclusivity through legal, technical, or market means.

predictable injection force medical

"distribution, and a predictable injection force and swelling profile1."

Predictable injection force is the consistent amount of push needed to deliver a dose from a syringe or auto‑injector across many uses and users. Investors care because predictable force signals reliable device performance, fewer dosing errors, stronger patient adherence, and smoother regulatory approval and manufacturing scale‑up — much like a car door that always closes with the same pressure, it reduces surprises and liability for drug-device combinations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practices

NEW YORK and DALLAS, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Platinum Dermatology Partners as the launch partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program.

Platinum will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs.

"This partnership with Obagi makes sense for us. They're taking a different approach to product development, and we have the clinical expertise to help them understand how trial data performs in real-world practice,” said Michael Pennington, Chief Executive Officer and Co-founder of Platinum Dermatology Partners. “Our injectors treat patients every day. That experience matters. This is the kind of work we should be doing. Obagi is thinking differently about product development, and that aligns with how we approach patient care. It's about raising the standard for aesthetic dermatology.”

The ALOHA Real-World Program is designed to give Platinum providers hands-on experience with Obagi saypha MagIQ while evaluating complete Obagi protocols. This approach aims to drive patient satisfaction and strengthen relationships between patients and their Platinum providers. The program includes a real-world clinical initiative supplemented by a structured evaluation process across multiple Platinum practices and providers, with standardized data capture.

Platinum will present initial findings at this September's annual Platinum Summit in Dallas, highlighting the benefits of the new product and its protocols within the Platinum network. Results will also be presented at key industry conferences to demonstrate the real-world impact of introducing this innovative injectable across Platinum’s practices.

“Partnering with Platinum is a clear statement of our intent to launch this new injectable on a foundation of robust clinical evidence, education, and integrated patient outcomes,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA program will serve as a platform for a differentiated launch strategy and underscore Obagi Medical’s commitment to delivering innovative products across every facet of skincare and now injectable aesthetics.”

Obagi^® saypha^® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. This technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.

For more information about ALOHA, visit https://obagi-professional.com/

About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.

About Platinum Dermatology Partners
Headquartered in Dallas, Texas, Platinum Dermatology Partners exists to empower the practice of exceptional dermatology through its vast resources and differentiated culture. Today, Platinum spans over 120 locations and nearly 400 providers across Arizona, California, Florida, Nevada, and Texas. Through Platinum’s differentiated, physician-driven model, the company creates a collaborative group practice setting with a focus on partnering with the most reputable physicians and providers seeking to elevate not only the patient care delivered but also benefit the specialty of dermatology at large. For more information about Platinum Dermatology Partners, please visit www.platinumderm.com.

About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.

Media Contact:
obagi@behrmancesa.com

Source: Waldencast plc

1.  Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
2. *Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the ALOHA program announced by Obagi Medical (WALD)?

The ALOHA program is a real-world clinical initiative to evaluate Obagi saypha MagIQ with standardized data capture across participating Platinum Dermatology practices.

Who is the launch partner for Obagi Medical’s ALOHA program (WALD)?

Platinum Dermatology Partners was selected as the launch partner and will run evaluations across its network of practices.

When will initial ALOHA findings for Obagi saypha MagIQ (WALD) be presented?

Initial findings are scheduled to be presented at Platinum’s annual Summit in Dallas in September 2026 and at industry conferences thereafter.

How extensive is Platinum Dermatology’s network for the ALOHA program?

Platinum spans over 120 locations with nearly 400 providers across multiple U.S. states, which will support multi-site data collection.

What technology does Obagi saypha MagIQ (WALD) use?

Obagi saypha MagIQ uses proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix aimed at consistent gel distribution and predictable injection force.

How will the ALOHA program affect Obagi Medical’s (WALD) launch strategy?

The company intends ALOHA to provide real-world clinical evidence, education, and integrated patient outcomes to support a differentiated injectable launch.